Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00478556 · ClinicalTrials.gov registry record · Phase 4
Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT
A Phase 4 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 4
- Development phase
- 300
- Enrollment target
NCT00478556 is a Phase 4 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 300 participants.
The verdict
NCT00478556, a Phase 4 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 300 participants
- Enrollment target
Study Summary
Patients who are scheduled by their health care provider for routine computed tomography (CT) scan will be asked to participate in this study. The primary purpose is to determine if there is a difference in patient preference for Omnipaque versus Gastroview as oral contrast for abdominal pelvic CT. A secondary objective is to evaluate if there is significant difference in bowel opacification for the two agents.
Interventions
- DRUG Omnipaque
- DRUG Gastroview
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00478556
The ClinicalTrials.gov registry entry for NCT00478556 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Omnipaque is the first listed.
NCT00478556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00478556 about?
NCT00478556 is a clinical study titled "Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT". Patients who are scheduled by their health care provider for routine computed tomography (CT) scan will be asked to participate in this study. The primary purpose is to determine if there is a difference in patient preference for Omnipaque versus Gastroview as oral contrast for abdominal pelvic CT. ...
What is the current status of trial NCT00478556?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 300 participants. The study started on 2007-08. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00478556?
The interventions under investigation include: Omnipaque (DRUG), Gastroview (DRUG).
Who is sponsoring clinical trial NCT00478556?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.